Another gene therapy safety scare hits
The clinical hold for Biomarin’s phenylketonuria project comes on the heels of an FDA adcom to discuss gene therapy toxicity.
Cytokine interest shows no sign of waning
Despite unconvincing results so far with next-gen IL-2 agents, plenty of groups are still crowding into this space.
Stock market correction sends biopharma back to the start of 2021
Covid-19 vaccine developers stand out as global drug stocks tread water in the first quarter.
No knockout blow from Rubius
Rubius shows the first hints of clinical anticancer activity, and is suddenly worth $2.4bn.
Curevac rides the Covid wave
Curevac’s market cap has ballooned almost fivefold since floating, sending the mRNA company into the record books.
Bristol bets on cytokines again
The company’s deal with Dragonfly shows that disappointments have not eliminated interest in cytokine approaches.
Legend joins the billion-dollar club
With a $3.2bn valuation ahead of its Nasdaq float – and a market cap that is now 50% higher – Legend Biotech enters the IPO record books.
Rubius confirms the worst
The collapse of Rubius’s first attempt to demonstrate the worth of its red blood cell platform proves that this company should never have gone public.
First blood: Rubius approaches its big test
The first clinical data from Rubius Therapeutics will show whether its lead project, RTX-134, has a future. More importantly, the readout is a test of its entire red…
